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Background/purpose: Biliary atresia is themost common reason for newborn cholestasis and pediatric liver trans-
plantation. Even after normalization of serumbilirubin after portoenterostomy,most patients require liver trans-
plantation by adulthood due to expanding fibrosis.We addressed contemporary outcomes of biliary atresia in the
Nordic countries.
Methods: Data on center and patients characteristics, diagnostic practices, surgical treatment, adjuvant medical
therapy after portoenterostomy, follow-up and outcomes were collected from all the Nordic centers involved
with biliary atresia care during 2005–2016.
Results: Of the 154 patients, 148 underwent portoenterostomy mostly by assigned surgical teams at median age
of 64 (interquartile range 37–79) days, and 95 patients (64%) normalized their serum bilirubin concentration
while living with native liver. Postoperative adjuvant medical therapy, including steroids, ursodeoxycholic acid
and antibiotics was given to 137 (93%) patients. Clearance of jaundice associated with young age at surgery
and favorable anatomic type of biliary atresia, whereas annual center caseload N3 patients and diagnostic proto-
col without routine liver biopsy predicted early performance of portoenterostomy. The cumulative 5-year native
liver and overall survival estimate was 53% (95% CI 45–62) and 88% (95% CI 83–94), respectively.
Portoenterostomy age b65 days and annual center caseload N3 patients were predictive for long-term native
liver survival, while normalization of serum bilirubin after portoenterostomy was the major predictor of both
native liver and overall 5-year survival.
Conclusions: The outcomes of biliary atresia in the Nordic countries compared well with previous European
studies. Further improvement should be pursued by active measures to reduce patient age at portoenterostomy.
Retrospective prognosis study: Level II.
© 2017 Elsevier Inc. All rights reserved.ion; PE, portoenterostomy; ERC,
s transhepatic cholangiography;
the Finnish Pediatric Research
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katu 11, 00029 HUS, Helsinki,
en).Biliary atresia (BA) is a severe cholangiopathy of infancy and themost
common reason for neonatal cholestasis and pediatric liver transplanta-
tion (LT) [1,2]. Pathophysiology of BA remains unclear, but rapidly
progressing biliary fibrosis leads to liver failure and death within 2 years
if untreated [1,2]. The first line surgical treatment is portoenterostomy
(PE), which typically resolves cholestasis in around half of the patients
[3–6]. Even after normalization of serum bilirubin levels, approximately
70–80% of patients require LT by adulthood due to portally expanding
ductal reaction and fibrosis associated with complications of ensuing
portal hypertension [1,2,7,8]. Outcome of PE carries vital prognostic
1510 M.P. Pakarinen et al. / Journal of Pediatric Surgery 53 (2018) 1509–1515significance in BA, because successful PE circumvents the highwaiting list
mortality during infancy and increases survival after LT compared to
primary LT [9–11].
Several patient-dependent factors at the time of PE such as young
age, favorable anatomyof the biliary tract remnant, absence of associated
congenital malformations and lower stage of liver fibrosis associate with
increased PE success rates and improved native liver survival [1,3,4,6,12].
Different postoperative adjuvant medications have been applied to
improve PE outcomes. Although randomized trials have failed to show
improvement in native liver survival by steroid treatment after PE
[13,14], steroids do seem to increase the proportion of patients who
clear their jaundice [15,16], while both steroids and ursodeoxycholic
acid have a beneficial effect on liver biochemistry [15–17]. Antibiotic
prophylaxis aims to prevent recurrent cholangitis episodes, which may
jeopardize survival with native liver [3,18]. Adjuvant therapy regimens
combining all three above mentioned medications have improved out-
comes in small retrospective studies [19,20]. Concentration of clinical
experience with BA management has also been shown to improve out-
comes, which has led to centralization of BA in several countries such
as UK and Finland [21,22].
In recent large European studies the clearance of jaundice rate and
the 5-year native liver survival have ranged between 36–55% and
39–46%, respectively [3–5], whereas no data on collective outcomes in
the Nordic countries are available. The Nordic countries has a combined
population of 27million people, share similar healthcare systems, socio-
economic status and educational level, and perform LT within a joint
organ exchange organization [11]. The principal aims of this study
were to characterize currentmanagement practices, analyze recent out-
comes of BA and assess factors affecting timing and success rate of PE
and native liver survival in the Nordic countries.
1. Patients and methods
1.1. Study design and data collection
This was an international multicenter retrospective observational
survey. All children with confirmed BA born in the Nordic countries
during 1.1.2005–30.6.2016 and followed-up at least for 4 months
were included. Data were collected locally by pediatric surgeons,
pediatric hepatologists and pediatricians in all Nordic centers involved
with the treatment of BA according to a collectively approved question-
naire and data extraction sheet. The participating centers included one
from Denmark (Copenhagen), Finland (Helsinki) and Norway (Oslo),
and three from Sweden (Stockholm, Gothenburg, Lund), while no BA
patients were reported from Iceland during this time period. All partici-
pating centers, excluding Lund, also perform pediatric LT within the
Scandiatransplant organ exchange organization [11]. The diagnosis of
BA was confirmed based on clinical history, laboratory results, surgical
findings, imaging such as perioperative cholangiography, endoscopic
retrograde cholangiography (ERC), percutaneous transhepatic cholan-
giography (PTC), liver biopsy and histopathological assessment of the
biliary remnant according to local preferences. Patients, who had under-
gone PE but proved to have Alagille syndrome (n = 3) were excluded.
Clinical practices concerning diagnostic modalities, surgical approach
to PE and medical therapy and esophageal variceal surveillance after PE
were enquired fromeach center. Data registered for each patient included
gender, ethnicity, timing and type of initial operativemanagement (PE, LT
or no operation), anatomic type of BA: extrahepatic bile duct obstruction
at the level of the common bile duct (type 1), the hepatic duct (type 2) or
the porta hepatis (type 3) according to the Japanese Society of Pediatric
Surgeons classification [23], observed associated congenital anomalies,
presence of asplenia or polysplenia, use of adjuvant medical therapy
after PE including steroids, ursodeoxycholic acid or antibiotic cholangitis
prophylaxis, clearance of jaundice, endoscopically detected esophageal
varices and listing, performance and timing of LT, and data on death.
Withdrawal of active treatment and reason for that was also registered.Latest available serum bilirubin concentrations and blood platelet levels
while living with native liver were recorded as surrogates of bile flow
and portal hypertension among native liver survivors [24]. Clearance of
jaundice was defined as decrease in total serum bilirubin below
20 μmol/l at any time point after PE. Physiological foramen ovale,
common anatomic variations of cardiac valves or vesicoureteral reflux
were not considered congenital malformations.
1.2. Ethics
The ethical review boards at participating hospitals approved the
study.
1.3. Statistical analysis
Continuous data are expressed asmedians with interquartile ranges
(IQR) and categorical data as frequencies unless otherwise stated.
Mann–Whitney U test was used to compare continuous variables, and
χ2 test to compare frequencies between groups. Cumulative native
liver survival (from birth to end of follow-up, LT or death), survival
after LT (from LT to end of follow-up or death) and overall survival
(from birth to end of follow-up or death) rates were analyzed using
Kaplan Meier curves with 95% confidence intervals (CI) and log-rank
test. In multivariate analyses, odd ratios (OR) with their 95% CIs were
generated with logistic regression models for predictors of age at PE
and clearance of jaundice, and hazard ratios (HR) with their 95% CIs
with Cox proportional hazards regression models for predictors of
5-year native liver survival. The proportional hazard hypotheses were
confirmed graphically and all variables in univariate analyses were
entered tomultivariate analyses. The variables formultivariate analyses
were chosen based on earlier literature [3–6]. The level of significance
was set at p b 0.05. Statistics were calculated with StatView® 512
software (Brain Power, Calabasas CA, USA).
2. Results
2.1. Center characteristics
Themedian number of patients treated in the participating six centers
annually ranged from 0.7 to 3.7, while only two centers managed over
three patients annually (Supplementary Table 1). Cholescintigraphy,
operative cholangiography and ultrasoundwere uniformly used diagnos-
tic investigations, whereas preoperative diagnostic liver biopsy, MRI, PTC
and ERC were less commonly employed. In five centers one surgeon or
surgical team operated all BA patients and none used laparoscopic surgi-
cal approach for PE. Five centers reported routine steroid use after PE,
while ursodeoxycholic acid, antibiotic prophylaxis and supplemental
fat-soluble vitamins were regularly prescribed after the surgery in all
centers. Two centers followed an endoscopic surveillance protocol for
esophageal varices.
2.2. Patient characteristics
In total, 158 patients were identified (Fig. 1). Treatment was with-
drawn in four cases (2.5%) due to untreatable severe associated
malformations affecting the heart or the central nervous system, and
theywere excluded from further analyses. Of the remaining 154 patients,
148 underwent PE and six (3.9%) had a primary LT. During the study
period, 58 patients had undergone a secondary LT after PE, and 137
(89%) of the actively treated patients were alive. Median follow-up
time among all patients was 4.9 (1.8–7.9) years.
Themajority of patientswere of European originwith a slight female
predominance (Table 1). The most unfavorable anatomic type of BA
(type 3) was observed in 82% of patients and 27% of patients had any
associated congenital malformations, which affected the spleen in 12%




















Fig. 1. Biliary atresia patients treated in the Nordic countries.
Table 2
Predictors for normalization of serum bilirubin concentration (b20 μmol/l) after
portoenterostomy during 2006–2016 in the Nordic countries. Clearance of jaundice rates









b65 days 55/77 (71) 0.056 1.98 (0.92–4.24) 0.079
N65 days 40/71 (56)
Gender
Female 50/79 (63) 0.807 0.95 (0.46–1.98) 0.900
Male 45/69 (65)
European ethnicity
Yes 76/119 (64) 0.868 0.92 (0.36–2.34) 0.863
No 19/29 (66)
Anatomic type of BA
type 1 or 2 20/24 (83) 0.031 3.70 (1.14–12.0) 0.030
type 3 74/123 (60)
Associated malformations
Yes 27/41 (66) 0.794 1.09 (0.39–3.03) 0.868
No 68/107 (63)
Splenic malformations
Yes 11/18 (61) 0.771 0.70 (0.18–2.81) 0.619
No 84/130 (65)
Center annual caseload
N3 54/79 (68) 0.258 1.53 (0.73–3.20) 0.262
b3 41/69 (59)
1511M.P. Pakarinen et al. / Journal of Pediatric Surgery 53 (2018) 1509–1515steroids, ursodeoxycholic acid and antibiotics following PE in order to
improve bile flow and prevent cholangitis (Table 1). Of the 148 patients,
who underwent PE, 137 (93%) had been treated with all these three
adjuvant medications postoperatively.2.3. Clearance of jaundice
In total, 95 of the 148 patients (64%) normalized their serum bilirubin
concentration after PE, while living with their native livers. The patients
who cleared their jaundice were median 10 days younger at PE
[58 (31–74) days] than those who did not [68 (45–84) days, p b 0.037].
In addition to younger age at surgery, favorable anatomy of the biliary
tract remnant (BA types 1 and 2)was associatedwith increased clearance
of jaundice rate after PE, and favorable anatomic type of BA remained
as the only significant prognosticator in multivariate analysis
(Table 2). Gender, ethnicity, associated congenital malformations,
splenic malformations or annual center caseload were not significantly
associated with clearance of jaundice.Table 1
Characteristics of actively treated biliary atresia patients during 2005–2016 in the Nordic
countries.
Number 154
Females, n (%) 83 (54)
European ethnicity, n (%) 124 (81)
Anatomic type of BA, n (%)
Type 1 10 (6.4)
Type 2 15 (9.7)
Type 3 126 (82)
Unknown 3 (1.9)
Associated congenital malformations, n (%) 42 (27)
Asplenia or polysplenia 19 (12)
Cardiac defect 10 (6.5)
Underwent portoenterostomy, n (%) 148 (96)
Age at portoenterostomy, days, median (interquartile range) 64 (37–79)
Medical therapy after portoenterostomy, n (%)
Corticosteroids 137 (93)
Ursodeoxycholic acid 144 (97)
Antibiotics 145 (98)
Normalized serum bilirubin b20 μmol/l, n (%) 95 (64)
Native liver survivors, n (%) 82 (53)
Follow-up age, years, median (interquartile range) 4.9 (2.4–7.3)
Serum bilirubin, μmol/l, median (interquartile range) 6 (4–15)
Blood platelets, 109/l, median (interquartile range) 230 (128–303)
Esophageal varices, n (%) 13 (16)2.4. Native liver survival and function
Including the six patients who underwent primary LT, the 5- and
10-year native liver survival estimates were 53% (95% CI 45–62) and
45% (95% CI 35–55), respectively (Fig. 2). The respective native liver
survival estimates were 55% (95% CI 47–64) and 47% (95% CI 37–57)
following PE. In univariate analysis PE age b65 days, annual center
caseload N3 andnormalization of serumbilirubin after PEwere predictive
for long-term native liver survival (Table 3 and Fig. 3). In multivariate
analysis, clearance of jaundice and annual center caseload N3 remained
highly predictive for the 5-year native liver survival, while the male
gender emerged as an additional statistically significant protective factor.
Ethnicities, anatomic types of BA or associated congenital malformations,
including the splenic ones, were not associated with native liver survival.
Among the 82 patients, who were currently alive with their native
livers, median serum bilirubin concentration and blood platelet level
was in the normal range (Table 1). Of them, 16% had endoscopically
verified esophageal varices, and only two were listed for LT.
2.5. Age at PE
Among the 148 patients, who underwent PE, the surgery was per-
formed at mean age of 60 (range 4–165) days (Table 1). Considering
the prognostic importance of the timing of PE for clearance of jaundice
and native liver survival, factors associated with the PE age were
addressed further. As shown in Table 4, associated congenital
malformations, especially the splenic ones, and annual center caseload
N3 patients were associated with a greater chance to undergo PE before
the age of 65 days, whereas routine use of diagnostic preoperative liver
biopsy markedly increased the risk of delayed surgery. The absolute age
at PEwasmedian 48 (30–69) days in patientswith associated congenital
anomalies versus 67 (39–83) days (p = 0.019) in those without; 44
(27–58) days in patients with splenic malformations versus 67
(39–80) days (p= 0.018) in those without; 52 (29–80) days in centers
with N3 annual patients versus 69 (45–79) days (p = 0.092) in centers
with b3 patients; and 72 (67–82) days in centers routinely using
diagnostic preoperative liver biopsy and 52 (28–78) days (p =
0.0002) in centers not routinely using preoperative liver biopsy. In














































































Fig. 2. Survival outcomes of 154 actively treated biliary atresia patients in the Nordic
countries. Kaplan Meier survival curves are shown for (A) native liver survival (B) post
liver transplantation survival and (C) overall survival.
Table 3
Predictors for native liver survival after portoenterostomyduring 2006–2016 in theNordic
countries. Five-year native liver KaplanMeier survival rateswere comparedwith log-rank
test andhazard ratios formultivariate analysiswere generatedwith Cox regressionmodel.







b65 days 77 66 (55–78) 0.005 1.51 (0.80–2.87) 0.207
N65 days 71 44 (32–56)
Gender
Female 79 51 (39–63) 0.301 0.47 (0.26–0.85) 0.012
Male 69 60 (48–72)
European
ethnicity
Yes 119 54 (45–64) 0.692 0.70 (0.35–1.41) 0.318
No 29 60 (42–79)
Anatomic type of
BA
type 1 or 2 24 66 (44–87) 0.187 1.36 (0.58–3.18) 0.485
type 3 123 53 (43–62)
Associated
malformations
Yes 41 62 (46–78) 0.612 1.02 (0.43–2.45) 0.966
No 107 53 (43–63)
Splenic
malformations
Yes 18 49 (24–74) 0.546 0.75 (0.25–2.24) 0.601
No 130 56 (47–65)
Center annual
caseload
N3 79 66 (54–77) 0.004 3.46 (1.76–6.81) 0.0003
b3 69 44 (32–56)
Clearance of
jaundice
b20 μmol/l 95 86 (78–94) b0.0001 32.0 (14.8–69.2) b0.0001
≥20 μmol/l 53 4.3 (0–10)
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delayed surgery by 4.3 fold (Table 4).
2.6. Liver transplantation
Six patients with a delayed diagnosis were transplanted primarily
without a prior PE at median age of 193 (154–281) days. In total, eight
patients (5.1%) died without receiving a liver graft and nine patients
died after LT (Fig. 1). Overall median age at LT was 0.82 (IQR 0.58–1.76,
range 0.40–10.1) years. Including all 64 transplanted patients, both the
5- and 10-year survival estimates after LT were 84% (95% CI 74–94)
(Fig. 2). The respective figures were 85% (95% CI 75–95) among the
patients, who had undergone a prior PE before transplanted. Ethnicities,
gender, anatomic types of BA, clearance of jaundice, associated con-
genital anomalies or splenic malformations were not associated with
the 5-year survival after LT (data not shown).2.7. Overall survival
The 5- and 10-year overall survival estimates were 88% (95% CI
83–94) and 87% (95% CI 81–93), respectively (Fig. 1). The 5-year overall
survival was higher among patients who cleared their jaundice after PE
[98% (95% CI 95–100)] than among those who did not [73% (95% CI
61–86)], p b 0.0001, and tended to be lower among the patients with
splenic malformations [77% (95% CI 57–97)] than in patients without
[90% (95% CI 84–95)], p = 0.064. In univariate analysis ethnicities,
gender, anatomic types of BA, annual center caseload or associated
congenital anomalies were not associated with the 5-year overall
survival (data not shown).
3. Discussion
The results of this study show that the clearance of jaundice rate, the
5-year native liver survival after PE and overall survival in the Nordic
countries compared well with previous European studies (Table 5).
Following PE, serum bilirubin concentration normalized in 64%, and
55% of the Nordic patients were alive with their native livers at
5 years. Their median serum bilirubin and blood platelet levels were in
the normal range, reflecting well-preserved native liver function. The
diagnostic and management practices of BA were relatively uniform in
theNordic countries, and thegreatmajority of thepatients receiveda com-
bination adjuvant therapy after PE, including steroids, ursodeoxycholic
acid and antibiotics.
Although only around 20–30% of the BA patients reach adulthood
without undergoing LT [7,25], extended native liver survival following
successful PE has the potential to improve overall prognosis of BA in
several ways. Firstly, it eliminates the increased waiting list mortality
during infancy after failed PE [9,11], which was reflected in the present
study by the 98% 5-year overall survival among thepatientswho cleared















































































Fig. 3.Native liver survival after portoenterostomy. Kaplan Meier survival curves and
log-rank p-values are shown according to (A) age at portoenterostomy (B) annual
center caseload and (C) clearance of jaundice.
Table 4
Predictors of portoenterostomy age b 65 days in patients with biliary atresia during
2006–2016 in the Nordic countries. Clearance of jaundice rates were compared with χ2
test and odd ratios for multivariate analysis were generated with logistic regression
model.
Predictor Portoenterostomy










Type 1 or 2 12/24 (50) 0.799 0.64 (0.24–1.73) 0.376
Type 3 65/123 (53)
Associated
malformations













Yes 7/34 (21) b0.0001 0.23 (0.08–0.70) 0.010
No 70/114 (61)
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survival rates after LT performed later in life [10]. Thirdly, extended
survival with native liver shortens the cumulative life-time exposure
to toxic side-effects of immunosuppressive medication by postponing
the need for LT.
Similarly to previous studies [3,4,26], our findings suggest that
patient age at surgery is the major prognostic factor for the success of
PE. In the present study, younger age at PE associated with both more
frequent clearance of jaundice and better long-term native liver survival.
As expected, clearance of jaundice, in turn, was clearly the most impor-
tant predictor of long-term native liver survival. In the present study,
the median patient age at PE (64 days) was 5 to 10 days higher than in
other recent European reports from France, theNetherlands and England
and Wales (Table 5), offering a logical and realistic target for further
improvement of the outcomes. While no screening programs for BA
have been yet established in the Nordic countries, all newborns visit
a primary care physician at the age of 4–6 weeks. Identification of
cholestatic infants at this point at the latest should leave enough timefor completion of a well-organized diagnostic protocol and timely
performance of PE before the age of 2 months. General awareness of
newborn cholestasis and the practice of routine measurement of serum
conjugated bilirubin in all jaundiced newborns older than 2 weeks
could be endorsed by active education [27–29]. Stool color card screening
has improved timing of PE, clearance of jaundice and native liver survival
in Taiwan and Japan, where BA incidence is considerably higher than in
Europe [30,31].
Despite early recognition of cholestatic newborns, the in-hospital
delay related to diagnostic protocols or logistic problems may also
unnecessarily delay the primary surgical care. We found that routine
use of preoperative diagnostic liver biopsy associatedwith delayed per-
formance of PE, whereas annual caseload N3 patients associated with
timely surgery. However, our survey did not look for differences in the
age at first referral to tertiary centers. Theoretically, the two centers
practicing routine liver biopsies may have received their referrals at a
later age than the others. Furthermore, the recently published joint
European and North American guidelines do in fact recommend
the use of liver biopsy for evaluation, in particular because of its high
specificity for BA [12,29]. Taken together, our findings imply, that any
chosen diagnostic pathway should be critically evaluated and optimized
to circumvent all avoidable delays, while increasing number of patients
may help to put final touches in these processes.
Besides age at PE, annual center caseload N3 patients associatedwith
improved native liver survival in the present survey. Centralization of
BA treatment and increasing caseloads has been shown to improve
native liver and overall survival in England and Wales as well as in
Finland andDenmark [21,22,32]. In contrast, no differences in outcomes
were observed between hospitals with the lowest and highest caseloads
in France and Canada ranging from below two to over 20 patients per
year [33,34]. BA treatment results are collectively influenced by the
quality of each step of the care, including early diagnosis, appropriate
surgery, postoperative management and follow-up. Because caseload
was not associated with normalization of serum bilirubin after PE,
other steps of the care pathway than surgical management are possibly
more sensitively affected by the caseload. In order to maximize surgical
Table 5
Recently reported outcomes of biliary atresia in Europe.




5-year native liver survival (%) 5-year overall survival (%)
England and Wales [5] 1999–2009 439 54 55 46 (95% CI 41–51)⁎ 90 (95% CI 88–93)
France [4] 2003–2009 339 59 36 39 (SE 3.3%)† 89 (SE 1.9%)
Netherlands [3] 1998–2008 104 59 38 42 (95% CI 32–52)†‡ 76 (95% CI 68–85)‡
Nordic countries (present) 2005–2016 154 64 64 53 (95% CI 45–62)⁎ 88 (83–94)
PE, portoenterostomy.
LT, liver transplantation.
⁎ Includes all patients.
† Includes patients who underwent PE.
‡ Four-year survival.
1514 M.P. Pakarinen et al. / Journal of Pediatric Surgery 53 (2018) 1509–1515experience, the relatively low caseload in each countrywas compensated
by concentrating PE operations to one surgeon in most Nordic centers.
In this study the presence of associated congenital anomalies, in-
cluding the splenic malformations, was not associated with decreased
clearance of jaundice or native liver survival rates in contrast to some
previous studies [4]. This could be explained by the observation that
these patients underwent PE at younger age than others possibly
following an earlier BA diagnosis inflicted by discovery and investiga-
tion of their associated congenital anomalies. The prevalence of splenic
malformations and congenital cardiac defects was comparable to
previously reported figs. [35,36], while occurrence of any associated
malformation was somewhat higher than in previous studies [35–37].
There is evidence on postoperative steroids improving clearance of
jaundice rate and liver biochemistry following PE [15,16], although
randomized trials have failed to demonstrate benefit of postoperative
steroids on native liver survival [13,14]. Ursodeoxycholic acid has a
favorable effect on serum liver biochemistry [17], while antibiotic
prophylaxis may reduce recurrent cholangitis episodes and improve
native liver survival after successful PE [3,18]. Interestingly, two retro-
spective studies have reported improvements in clearance of jaundice
and native liver survival rates after PE with postoperative adjuvant
therapy consisting of steroids, ursodeoxycholic acid and antibiotics
[19,20]. Although our study was not design to address the effectiveness
this triple adjuvant therapy, it could be one factor contributing to the
achieved outcomes. Obviously, a randomized controlled trial would be
the optimal way to address this question further.
This study had several limitations. Because only two centers followed
an endoscopic surveillance protocol, the incidence of varices ismost likely
markedly underestimated. We did not collect data on cholangitis
episodes, serum bilirubin concentrations at set time points or the time
taken to achieve clearance of jaundice and thus were not able address
their effects on survival outcomes. Nor did we collect details or duration
of postoperative medical therapy following PE. However, availability
and accuracy of such data always remains imperfect in a retrospective
study design and our major aim was to assess management characteris-
tics and outcomes of BA in the Nordic countries.
In conclusion, these findings demonstrate that current outcomes of
BA in the Nordic countries are well comparable to previous European
studies and annual caseload is highly predictive for the 5-year native
liver survival. Further improvement should be pursued by multimodal
active measures to reduce patient age at PE. The high rates of clearance
of jaundice and native liver survival after PEwere achievedwith the use
of steroids, ursodeoxycholic acid and antibiotics as a postoperative adju-
vant medical therapy in over 93% of patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jpedsurg.2017.08.048.References
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